1228631-64-8

Basic information

• Product Name: tert-butyl 6-oxo-2,7-diazaspiro[4.5]decane-2-carboxylate
• Synonyms: tert-butyl 6-oxo-2,7-diazaspiro[4.5]decane-2-carboxylate;2-Boc-6-oxo-2,7-diaza-spiro[4.5]decane
• CAS NO: 1228631-64-8
• Molecular Formula: C₁₃H₂₂N₂O₃
• Molecular Weight: 254.32538
• Mol File: 1228631-64-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 6-oxo-2,7-diazaspiro[4.5]decane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-oxo-2,7-diazaspiro[4.5]decane-2-carboxylate(1228631-64-8)
• EPA Substance Registry System: tert-butyl 6-oxo-2,7-diazaspiro[4.5]decane-2-carboxylate(1228631-64-8)

Safety Data

• Hazardous Substances Data: 1228631-64-8(Hazardous Substances Data)

Upstream product

• 1383575-16-3 1-(tert-butyl) 3-methyl 3-(2-cyanoethyl)pyrrolidine-1,3-dicarboxylate 
• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 

Downstream Products

• 1383575-66-3 6-Oxo-7-[1-(toluene-4-sulfonyl)-1H-indol-3-ylmethyl]-2,7-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester 
• 1383575-67-4 2-(4-methoxy-6-methyl-pyrimidin-2-yl)-7-[1-(toluene-4-sulfonyl)-1H-indol-3-ylmethyl]-2,7-diaza-spiro[4.5]decan-6-one 

Relevant articles and documents

AZACARBAZOLE BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

DI/TRI-AZA-SPIRO-C9-C11ALKANES

The invention relates to compounds of the formula I A-D-C(R1)2-B (I), in which A and B are aromatic ring systems and wherein D is selected from the groups D1 to D5 and the other substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.